Abstract
Gout has become a global problem, antiuric acid formula (AAF) is a clinical prescription highly effective in reducing uric acid levels. In order to find its quality control standards and contribute to the treatment of gout in the future, we adopted high-performance liquid chromatography and orbitrap liquid chromatography–mass spectrometry to establish fingerprints of 13 batches of AAF. The different batches of AAF were tested the activity of inhibit uric acid by the xanthine oxidase inhibition experiment. Grey relational analysis and bio-activity validation to assess the spectrum–effect relationship. Finally, we choose puerarin, calycosin-7-O-beta-d-glucoside and puerarin apioside as the AAF quality control component, and its average content is 6036.006 μg/g, 296.113 μg/g and 878.285 μg/g. As the quality control components of AAF, puerarin, calycosin-7-O-beta-d-glucoside and puerarin apioside can be of great significance for the treatment of gout and gout related research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
